



Ganymed Pharmaceuticals AG - Corporate overview

Founded

2001 as a spin-off from the Universities of Mainz and Zurich

Location

Mainz, Germany

Number of employees

70

Focus

Discovery and development of truly tumor specific and effective ideal monoclonal antibodies (iMAB) for the treatment of solid cancers with high unmet medical need

Products (clinical)

Claudiximab (iMAB362)

- GC182 target (CLDN18.2)
- Indications: metastatic gastro-esophageal, pancreatic and lung cancer

Products (preclinical)

iMAB512

- GT512 target
- Indications: ovarian and lung cancer

iMAB468

- GT468 target
- Indications: breast, lung and ovarian cancer

Three other projects with cancer specific targets at different stages under validation for antibody development to treat the following cancers:

- Melanomas
- prostate cancers
- lung cancers
- breast cancers
- colorectal cancers.

Company Profile

GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets (iMAB) in solid cancers.


GANYMED's unique expertise in pinpointing truly cancer specific proprietary targets is the basis for the company's growing sustainable pipeline of antibody therapeutics with unique tumor specificity targeting solid cancers with high medical need.

Because GANYMED's proprietary cell surface cancer targets have unmatched tumor cell specificity, iMABs can efficiently kill tumor cells without harming normal tissues. Freed from concerns relating to toxicity in normal tissues. GANYMED's iMABs can unleash the full potential of therapeutic antibodies via four separate but synergistic biological attacks specifically focused on the cancer cells alone:

- Direct suppression of tumor growth
- Antibody dependent cellular cytotoxicity (ADCC)
- Antibody dependent complement cell lysis (CDC)
- Induction of apoptosis

As a consequence of this quadruple mode of cancer cell killing, GANYMED's iMABs have greatly improved pharmacological properties by combining critical success parameters for better clinical efficacy and reduced treatment-related toxicity, including:

- A broader therapeutic window, and
- Higher potency.



GANYMED's cell surface targets have unique cancer specificity



Investors

ATS Beteiligungsverwaltung GmbH
Future Capital AG
MIG AG
Private investors

Management Team

PD Özlem Türeci, MD, CEO & CSO
Dirk L. Sebastian, CFO & COO
Rainer Wessel, PhD, CBO & Spokesman

Supervisory Board

Prof. Rolf Krebs, MD (Chair)
Prof. Christoph Huber, MD (Vice Chair)
Wolfgang Boorberg
Helmut Jeggle
Axel H. Leimer
Walter Pörschmann

Scientific Advisors

Ulrich Granzer, PhD
Prof. Hans Hengartner, PhD
Prof. Christoph Huber, MD
Richard B. Stead, MD
Prof. Rolf Zinkernagel, MD (Nobel Laureate)

Product Pipeline

GANYMED's broad target and antibody pipeline is focusing on solid cancer blockbuster markets with high unmet medical need. Three different antibody projects each directed at different truly cancer specific target are currently in development:

- **iMAB362 (Claudiximab)** - is an iMAB directed against the GC182 (CDLN18.2) target, a gastric differentiation protein that is expressed at the cell surface in 70% of gastric cancers, 50% of pancreatic cancers, 30% of esophageal cancers, and 25% of non-small cell lung cancers (NSCLC). A clinical first-in-human Phase I multicenter study with iMAB362 in patients with metastatic adenocarcinoma of the stomach and lower esophagus was successfully concluded in June 2010. The study demonstrated excellent safety of iMAB362 up to a dose of 1g/sqm. Commencement of the follow-on clinical Phase IIa study in advanced gastro-esophageal cancer patients is planned for the third quarter of 2010.
- **iMAB512** - is an iMAB directed against a cell surface antigen (internal code GT512) that is expressed in 70% of ovarian cancers and 50% of NSCLC cancers. This iMAB is currently in preclinical development.
- **iMAB468** - is an iMAB directed against a target (internal code GT468) that is expressed at the cell surface in 80% of breast cancers, 60% of NSCLC cancers, and 20% of ovarian cancers. This iMAB is currently in preclinical development.

GANYMED has three other projects with truly cancer specific targets in validation for antibody development. Like all GANYMED targets, also these targets are expressed with significant prevalence in solid cancers with high unmet medical need including melanomas, prostate cancers, lung cancers, breast cancers and colorectal cancers.

Investors

GANYMED is a well-financed private German biopharmaceutical company supported by highly successful investors with a wealth of experience in backing successful life science entrepreneurs. GANYMED's majority shareholder is ATS Beteiligungsverwaltung GmbH. The other investors include: Future Capital AG, MIG AG and private individuals.

Contact details

GANYMED Pharmaceuticals AG
Freiligrathstrasse 12
D-55131 Mainz
Germany

Phone: +49 (0) 6131-1440 100
Fax: +49 (0) 6131-1440 114

E-Mail: info@GANYMED.ag
Web: www.GANYMED.ag

